# NCT05433142 (NCT05433142)

> Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05433142
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Xencor, Inc.
- Conditions: Clear Cell Renal Cell Carcinoma
- Interventions: XmAb819
- Enrollment: 307
- Primary outcome: Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)
- Primary outcome: Incidence of dose limiting toxicities (DLTs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05433142